UAE Generic Drugs Market By Type (Small Molecule Generics v/s Biosimilars), By Mode of Drug Delivery (Oral, Topical, Parenteral, Others), By Form (Tablet, Capsule, Injection, Others), By Source (In House v/s Contract Manufacturing Organizations), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Application (Cardiovascular Diseases, Diabetes, Neurology, Oncology, Anti-Inflammatory Diseases, Others), By Region, Competition Forecast & Opportunities, 2027
UAE generic drugs market is anticipated to register growth with an impressive CAGR in the forecast period, 2023-2027, on the account of surging demand for affordable healthcare services. Increasing demand for medicines and drugs for chronic patients exposed to prolonged medication further demand generic drugs over branded drugs, thereby driving the growth of the UAE generic drugs market in the upcoming five years. Easier FDA approvals for generic drugs also support the growth of the UAE generic drugs market in the next five years.
Generic drugs are medicines that have the same active ingredients, same safety standards, are equally effective, and are of high quality as much as the branded drugs but are much cheaper than the branded drugs. The dosage, therapeutic activity, administration, and formulation of the generic drug are the same as the branded drugs. The major difference between the two is the cost of drugs and inert ingredients that give the drug its color, shape, or taste. Once the patent of the branded drug expires, generic drug manufacturers duplicate the chemical formulas of the branded drug to manufacture a generic drug. Manufacturing and patient use do not require extensive clinical trials to prove safety and efficiency. If the molecule formula and safety standards are followed during the manufacturing the drug is soon released in the market thus making the manufacturing process cost-efficient and thus the low prices of the drugs. Examples of generic drugs include “metformin”. Metformin is a generic drug for the branded drug, “Glucophage” which is used for diabetes. Similarly, “metoprolol” is used for hypertension instead of “Lopressor”.
Growing Pharmaceutical Industry Promises Market Growth
The UAE pharmaceutical industry is expanding rapidly due to surging demands for pharmaceutical products, increasing imports of pharmaceuticals to satisfy the surging demands as well as increased manufacturing of generic drugs by local manufacturers that further drives the growth of the UAE generic drugs market in the upcoming five years. According to government sources, the demand for pharmaceuticals in Dubai region alone would exceed 5 million, further, expansion is also expected due to the overall increasing population all over the country.
The pharmaceutical manufacturing landscape in UAE has been dominated by generic drug manufacturers and contract manufacturing organizations (for medical therapeutics). Although global giants are penetrating the market large number of manufacturing units for branded drugs are not yet flooding the country. The market players have made Dubai a regional hub due to a favorable tax environment, well-developed infrastructure, and a bustling labor force.
Increasing Chronic Diseases Instances Drive Market Growth
Increasing instances of chronic diseases like cardiovascular diseases, cancer, diabetes, etc. further drive the growth of the UAE generic drugs market in the upcoming five years. Due to cardiovascular diseases over 40% of deaths are caused every year in the UAE. Demands for the drugs for a prolonged period due to chronic conditions of the diseases further support the growing demand for generic drugs to reduce the treatment costs of the diseases. By the year 2021, the country had 6176 generic drugs being manufactured that cost less than 60% than the branded medicines making healthcare much more h affordable for the common population. The country had 16 factories ithe n medical and pharmaceutical industry and three others for intravenous fluids, laboratories, and medical supplies in 2021 and the count is increasing further. The government is also investing in outpatient healthcare services that aid the market, the value of UAE outpatient healthcare expenditure in 2020 was USD7.41 billion.
Market Segmentation
The UAE generic drugs market is segmented by type, mode of drug delivery, form, source, distribution channel, application, competitional landscape, and regional distribution. Based on type, the market is differentiated between small molecule generics and biosimilars. By mode of drug delivery, the market is further segmented into oral, topical, parenteral, and others. The form-based market is fragmented into a tablet, capsules, injections, and others. By source, the market is differentiated between in-house and contract manufacturing organizations. Based on distribution channels, the market is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. By application, market segments are defined into cardiovascular diseases, diabetes, neurology, oncology, anti-inflammatory diseases, and others. The market analysis also studies the regional segmentation to devise regional market segmentation, divided among Abu Dhabi region, Dubai region, Sharjah region, and the rest of UAE.
Company Profile
Gulf Pharmaceutical Industries (Julphar), Sanofi UAE, Sun Pharma Global FZE, Abbott Laboratories SA, Eli Lilly & Company UAE, Mylan UAE, and GlaxoSmithKline & Neopharma, among others is a partial list of major market players of the companies responsible for the growth of UAE generic drugs market.
Report Scope:
In this report, UAE generic drugs market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in UAE generic drugs market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
Generic drugs are medicines that have the same active ingredients, same safety standards, are equally effective, and are of high quality as much as the branded drugs but are much cheaper than the branded drugs. The dosage, therapeutic activity, administration, and formulation of the generic drug are the same as the branded drugs. The major difference between the two is the cost of drugs and inert ingredients that give the drug its color, shape, or taste. Once the patent of the branded drug expires, generic drug manufacturers duplicate the chemical formulas of the branded drug to manufacture a generic drug. Manufacturing and patient use do not require extensive clinical trials to prove safety and efficiency. If the molecule formula and safety standards are followed during the manufacturing the drug is soon released in the market thus making the manufacturing process cost-efficient and thus the low prices of the drugs. Examples of generic drugs include “metformin”. Metformin is a generic drug for the branded drug, “Glucophage” which is used for diabetes. Similarly, “metoprolol” is used for hypertension instead of “Lopressor”.
Growing Pharmaceutical Industry Promises Market Growth
The UAE pharmaceutical industry is expanding rapidly due to surging demands for pharmaceutical products, increasing imports of pharmaceuticals to satisfy the surging demands as well as increased manufacturing of generic drugs by local manufacturers that further drives the growth of the UAE generic drugs market in the upcoming five years. According to government sources, the demand for pharmaceuticals in Dubai region alone would exceed 5 million, further, expansion is also expected due to the overall increasing population all over the country.
The pharmaceutical manufacturing landscape in UAE has been dominated by generic drug manufacturers and contract manufacturing organizations (for medical therapeutics). Although global giants are penetrating the market large number of manufacturing units for branded drugs are not yet flooding the country. The market players have made Dubai a regional hub due to a favorable tax environment, well-developed infrastructure, and a bustling labor force.
Increasing Chronic Diseases Instances Drive Market Growth
Increasing instances of chronic diseases like cardiovascular diseases, cancer, diabetes, etc. further drive the growth of the UAE generic drugs market in the upcoming five years. Due to cardiovascular diseases over 40% of deaths are caused every year in the UAE. Demands for the drugs for a prolonged period due to chronic conditions of the diseases further support the growing demand for generic drugs to reduce the treatment costs of the diseases. By the year 2021, the country had 6176 generic drugs being manufactured that cost less than 60% than the branded medicines making healthcare much more h affordable for the common population. The country had 16 factories ithe n medical and pharmaceutical industry and three others for intravenous fluids, laboratories, and medical supplies in 2021 and the count is increasing further. The government is also investing in outpatient healthcare services that aid the market, the value of UAE outpatient healthcare expenditure in 2020 was USD7.41 billion.
Market Segmentation
The UAE generic drugs market is segmented by type, mode of drug delivery, form, source, distribution channel, application, competitional landscape, and regional distribution. Based on type, the market is differentiated between small molecule generics and biosimilars. By mode of drug delivery, the market is further segmented into oral, topical, parenteral, and others. The form-based market is fragmented into a tablet, capsules, injections, and others. By source, the market is differentiated between in-house and contract manufacturing organizations. Based on distribution channels, the market is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. By application, market segments are defined into cardiovascular diseases, diabetes, neurology, oncology, anti-inflammatory diseases, and others. The market analysis also studies the regional segmentation to devise regional market segmentation, divided among Abu Dhabi region, Dubai region, Sharjah region, and the rest of UAE.
Company Profile
Gulf Pharmaceutical Industries (Julphar), Sanofi UAE, Sun Pharma Global FZE, Abbott Laboratories SA, Eli Lilly & Company UAE, Mylan UAE, and GlaxoSmithKline & Neopharma, among others is a partial list of major market players of the companies responsible for the growth of UAE generic drugs market.
Report Scope:
In this report, UAE generic drugs market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- UAE Generic Drugs Market, By Type:
- Small Molecule Generics
- Biosimilars
- UAE Generic Drugs Market, By Mode of Drug Delivery:
- Oral
- Topical
- Parenteral
- Others
- UAE Generic Drugs Market, By Form:
- Tablet
- Capsule
- Injection
- Others
- UAE Generic Drugs Market, By Source:
- In House
- Contract Manufacturing Organizations
- UAE Generic Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- UAE Generic Drugs Market, By Application:
- Cardiovascular Diseases
- Diabetes
- Neurology
- Oncology
- Anti-Inflammatory Diseases
- Others
- UAE Generic Drugs Market, By Region:
- Abu Dhabi region
- Dubai region
- Sharjah region
- Rest of UAE
Company Profiles: Detailed analysis of the major companies present in UAE generic drugs market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
2. RESEARCH METHODOLOGY
3. IMPACT OF COVID-19 ON UAE GENERIC DRUGS MARKET
4. VOICE OF CUSTOMER
5. EXECUTIVE SUMMARY
6. UAE GENERIC DRUGS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type (Small Molecule Generics v/s Biosimilars)
6.2.2. By Mode of Drug Delivery (Oral, Topical, Parenteral, Others)
6.2.3. By Form (Tablet, Capsule, Injection, Others)
6.2.4. By Source (In House v/s Contract Manufacturing Organizations)
6.2.5. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
6.2.6. By Application (Cardiovascular Diseases, Diabetes, Neurology, Oncology, Anti-Inflammatory Diseases, Others)
6.2.7. By Company (2021)
6.2.8. By Region
6.3. Product Market Map
7. UAE SMALL MOLECULE GENERIC DRUGS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Mode of Drug Delivery
7.2.2. By Form
7.2.3. By Source
7.2.4. By Distribution Channel
7.2.5. By Application
8. UAE BIOSIMILAR GENERIC DRUGS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Mode of Drug Delivery
8.2.2. By Form
8.2.3. By Source
8.2.4. By Distribution Channel
8.2.5. By Application
9. MARKET DYNAMICS
9.1. Drivers
9.2. Challenges
10. MARKET TRENDS & DEVELOPMENTS
11. POLICY & REGULATORY LANDSCAPE
12. UAE ECONOMIC PROFILE
13. COMPETITIVE LANDSCAPE
13.1. Competition Outlook
13.2. Company Profiles
13.2.1. Gulf Pharmaceutical Industries (Julphar)
13.2.2. Sanofi UAE
13.2.3. Sun Pharma Global FZE
13.2.4. Abbott Laboratories SA
13.2.5. Eli Lilly & Company UAE
13.2.6. Mylan UAE
13.2.7. GlaxoSmithKline & Neopharma
14. STRATEGIC RECOMMENDATIONS
2. RESEARCH METHODOLOGY
3. IMPACT OF COVID-19 ON UAE GENERIC DRUGS MARKET
4. VOICE OF CUSTOMER
5. EXECUTIVE SUMMARY
6. UAE GENERIC DRUGS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type (Small Molecule Generics v/s Biosimilars)
6.2.2. By Mode of Drug Delivery (Oral, Topical, Parenteral, Others)
6.2.3. By Form (Tablet, Capsule, Injection, Others)
6.2.4. By Source (In House v/s Contract Manufacturing Organizations)
6.2.5. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
6.2.6. By Application (Cardiovascular Diseases, Diabetes, Neurology, Oncology, Anti-Inflammatory Diseases, Others)
6.2.7. By Company (2021)
6.2.8. By Region
6.3. Product Market Map
7. UAE SMALL MOLECULE GENERIC DRUGS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Mode of Drug Delivery
7.2.2. By Form
7.2.3. By Source
7.2.4. By Distribution Channel
7.2.5. By Application
8. UAE BIOSIMILAR GENERIC DRUGS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Mode of Drug Delivery
8.2.2. By Form
8.2.3. By Source
8.2.4. By Distribution Channel
8.2.5. By Application
9. MARKET DYNAMICS
9.1. Drivers
9.2. Challenges
10. MARKET TRENDS & DEVELOPMENTS
11. POLICY & REGULATORY LANDSCAPE
12. UAE ECONOMIC PROFILE
13. COMPETITIVE LANDSCAPE
13.1. Competition Outlook
13.2. Company Profiles
13.2.1. Gulf Pharmaceutical Industries (Julphar)
13.2.2. Sanofi UAE
13.2.3. Sun Pharma Global FZE
13.2.4. Abbott Laboratories SA
13.2.5. Eli Lilly & Company UAE
13.2.6. Mylan UAE
13.2.7. GlaxoSmithKline & Neopharma
14. STRATEGIC RECOMMENDATIONS
